ClinicalTrials.gg
RecruitingNCT07871409MARITIME-PENUpdated Nov 9, 2026

Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight

A Phase 3 interventional study of Maridebart cafraglutide and Autoinjector in Obesity and Overweight, sponsored by Amgen. Recruiting at 25 sites in 2 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 9, 2026Now RecruitingFirst site in Puerto Rico+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
230
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing maridebart cafraglutide in Obesity — 9 open to participants now, 17 under way, 11 of them phase 3. maridebart cafraglutide · Obesity.

Planned enrollment
17th of 28
230 · median 275
Started
2026
with 9 others
Phase 3
11 of 28
6 open now
Primary completion
2027-06
later than 5 of 16 live
Registered
26th of 28
by date
Lead sponsor
28 of 28
Amgen

Among the 28 studies testing maridebart cafraglutide in Obesity, this one is the 17th largest by planned enrollment, is one of 10 that started in 2026, is one of 11 in phase 3, reaches primary completion later than 5 of the 16 other live ones, and was the 26th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 28 studies testing maridebart cafraglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About maridebart cafraglutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing maridebart cafraglutide in Obesity, or all of them as a file.
02

Study summary

The main objective of this study is to assess participants' ability to self-administer subcutaneous doses of maridebart cafraglutide at home using an autoinjector device.

03

Conditions studied

  • Obesity
  • Overweight

Keywords

  • AMG 133
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) ≥ 30 kilograms per meter square (kg/m\^2), or BMI ≥ 27 to \< 30 kg/m\^2 with one of the following:

    • hypertension: treated, or with systolic blood pressure ≥ 130 millimeters of mercury (mmHg) or diastolic blood pressure ≥ 80 mmHg
    • dyslipidemia: treated or previously diagnosed high cholesterol, high triglycerides, or low HDL cholesterol.
    • history of obstructive sleep apnea
    • history of cardiovascular disease
    • history of fatty liver disease (including metabolic dysfunction-associated steatotic liver disease [MASLD] or metabolic dysfunction-associated steatohepatitis [MASH])
  • At least 1 unsuccessful attempt at weight loss by diet and exercise.
  • for females.
  • Willingness to follow trial procedures for the duration of the trial.

Exclusion criteria

Exclusion Criteria:

  • Obesity induced by other endocrinologic disorders.
  • Change in body weight > 5 kg within last 90 days.
  • Previous or planned surgical, endoscopic, or device-based treatment for obesity.
  • History of within the past 5 years.
  • Type 1 or Type 2 diabetes mellitus.
  • History of chronic pancreatitis or history of acute pancreatitis within last 180 days.
  • Family or personal history of medullary thyroid cancer.
  • Previous participation in a Maridebart Cafraglutide trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
230 participants (estimated)

Study arms

  • Experimental
    Maridebart cafraglutide

    Participants will receive 8 total doses of subcutaneous (SC) injections of maridebart cafraglutide.

    Drug: Maridebart cafraglutide · Device: Autoinjector

Interventions

  • Administered subcutaneously.

    Also known as: AMG 133, MariTide

  • DeviceAutoinjector

    The AI will be used by participants to self-administer SC doses of maridebart cafraglutide.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Successfully Self-inject a Full Dose Among Those Who Attempted Injection at Each Home Administration

    Time frame: Weeks 12, 16, and 20

  2. Percentage of Participants Who Successfully Self-inject a Full Dose Among All Participants Who Entered the Home Self-administration Phase at Each Scheduled Home Administration

    Time frame: Weeks 12, 16, and 20

Secondary outcomes

  1. Number of Participants Who Experience Device-related Adverse Events

    Time frame: Up To 37 weeks

  2. Number of Participants Who Experience Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: TEAEs: From baseline (Day 1) up to end of trial (approximately 37 weeks). SAEs: From screening (Day -28) up to end of trial (approximately 41 weeks).

  3. Plasma Concentration of Maridebart Cafraglutide at Week 24

    Time frame: Week 24

  4. Percent Change From Baseline in Body Weight at Week 24

    Time frame: Baseline and Week 24

07

Study locations

25 of 25 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Jun 2027, 8 months after the start.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 8 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2026
First posted
Oct 13, 2026
StartActual
Oct 15, 2026
Primary completionEst.
Jun 16, 2027
CompletionEst.
Sep 8, 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 9, 2026
Sites
24 sites added — first site in Puerto Rico. Charter Research - The Villages is now Recruiting
Show 24 added (23 United States, 1 Puerto Rico)
  • Apex Clinical Research · San Diego, United States
  • Southern Clinical Research · Miami, United States
  • Research Institute of South Florida · Miami, United States
  • Clinical Neuroscience Solutions LLC · Orlando, United States
  • Florida Institute for Clinical Research · Orlando, United States
  • Nsc Research · Johns Creek, United States
  • North Georgia Clinical Research · Woodstock, United States
  • Solaris Clinical Research · Meridian, United States
  • Alliance For Multispecialty Research - Oak Brook · Oak Brook, United States
  • Flourish Research · Bowie, United States
  • Rochester Clinical Research · Rochester, United States
  • Centricity Research · Morehead City, United States
  • Centricity Research Dublin · Columbus, United States
  • Epic Medical Research - Oklahoma · Chickasha, United States
  • Tribe Clinical Research LLC Dba Mountain View Clinical Research · Greenville, United States
  • Cedar Health Research- Texas Native Health · Dallas, United States
  • Cedar Health Research, LLC · Dallas, United States
  • Soma Clinical Trials, LLC · Denison, United States
  • Epic Medical Research - Red Oak · DeSoto, United States
  • Biopharma Informatic, LLC · Houston, United States
  • Research Physicians Network LLC · Houston, United States
  • Texas Institute of Cardiology · McKinney, United States
  • North Hills Medical Research · North Richland Hills, United States
  • Latin Clinical Trial Center · San Juan, Puerto Rico
Nov 9, 2026
Start date
Oct 28, 2026→Oct 15, 2026 (actual)
Nov 9, 2026
Registered
First appeared on the registry
Oct 13, 2026
Show all 2 updates
  1. Nov 9, 2026
    Not yet recruiting→Recruiting
    24 sites added — first site in Puerto Rico. Charter Research - The Villages is now Recruiting
    Show 24 added (23 United States, 1 Puerto Rico)
    • Apex Clinical Research · San Diego, United States
    • Southern Clinical Research · Miami, United States
    • Research Institute of South Florida · Miami, United States
    • Clinical Neuroscience Solutions LLC · Orlando, United States
    • Florida Institute for Clinical Research · Orlando, United States
    • Nsc Research · Johns Creek, United States
    • North Georgia Clinical Research · Woodstock, United States
    • Solaris Clinical Research · Meridian, United States
    • Alliance For Multispecialty Research - Oak Brook · Oak Brook, United States
    • Flourish Research · Bowie, United States
    • Rochester Clinical Research · Rochester, United States
    • Centricity Research · Morehead City, United States
    • Centricity Research Dublin · Columbus, United States
    • Epic Medical Research - Oklahoma · Chickasha, United States
    • Tribe Clinical Research LLC Dba Mountain View Clinical Research · Greenville, United States
    • Cedar Health Research- Texas Native Health · Dallas, United States
    • Cedar Health Research, LLC · Dallas, United States
    • Soma Clinical Trials, LLC · Denison, United States
    • Epic Medical Research - Red Oak · DeSoto, United States
    • Biopharma Informatic, LLC · Houston, United States
    • Research Physicians Network LLC · Houston, United States
    • Texas Institute of Cardiology · McKinney, United States
    • North Hills Medical Research · North Richland Hills, United States
    • Latin Clinical Trial Center · San Juan, Puerto Rico
    Start date Oct 28, 2026→Oct 15, 2026 (now actual)
  2. Oct 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07871409
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Oct 13, 2026
Start date
Oct 15, 2026
Primary completion
Jun 16, 2027 (estimated)
Completion
Sep 8, 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Amgen Call Center
Contact
medinfo@amgen.com
866-572-6436
MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maridebart cafraglutide

Start the discussion